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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new
coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people
in 214 countries worldwide. After inhalation, aerosols containing SARS-CoV-2 penetrate to the depths of the lungs and cause
severe pneumonia, alveolar injury, and life-threatening acute respiratory distress syndrome (ARDS). Since there are no specific
drugs or vaccines available to cure or prevent COVID-19 infection and COVID-19-related ARDS, a new therapeutic agent
which will support oxygen supply and, at the same time, efficiently alleviate SARS-CoV-2-induced lung inflammation is urgently
needed. Due to their potent immuno- and angiomodulatory characteristics, mesenchymal stem cells (MSCs) may increase
oxygen supply in the lungs and may efficiently alleviate ongoing lung inflammation, including SARS-CoV-2-induced ARDS. In
this review article, we described molecular mechanisms that are responsible for MSC-based modulation of immune cells which
play a pathogenic role in the development of SARS-CoV-2-induced ARDS and we provided a brief outline of already conducted
and ongoing clinical studies that increase our understanding about the therapeutic potential of MSCs and their secretome in the
therapy of COVID-19-related ARDS.
1. Introduction
From December 2019, the world population has been faced
with a new coronavirus disease (COVID-19) caused by
the novel severe acute respiratory syndrome coronavirus
(SARS-CoV-2) [1]. As a highly transmittable virus, SARS-
CoV-2 rapidly spread and, in just ten months, infected more
than 40 million people in 214 countries worldwide [2].
Since the primary route of transmission of SARS-CoV-2
is through respiratory droplets, the lungs are severely injured
in COVID-19 patients [3]. After inhalation, aerosols contain-
ing SARS-CoV-2 penetrate the depths of the lungs and cause
severe pneumonia, alveolar injury, and life-threatening acute
respiratory distress syndrome (ARDS) [4]. The initial step in
the development of SARS-CoV-2-induced ARDS is the
interactions between the SARS-CoV-2 spike (S) protein and
angiotensin-converting enzyme 2 (ACE2) and transmem-
brane protease serine 2 (TMPRSS2) of alveolar type II cells
(AT2) (Figure 1) [3]. TMPRSS2 splits the S protein into
two functional subunits, S1 which interacts with ACE2 and
S2 that is further cleaved and activated by TMPRSS2. This
structural and conformational change in the S protein
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facilitates fusion of viral envelope with the cell membrane of
AT2 cells, enabling endocytic entry of the virus in the target
cell. Immediately after viral RNA is released into the cyto-
plasm of AT2 cell, the translational machinery of AT2 cell
is used for the synthesis of the essential structural and
functional viral proteins (proteases 3CLpro and PLpro,
RNA-dependent RNA polymerase and helicase) [3, 4]. These
proteins, as well as other structural components of SARS-
CoV-2, are recognized by immune cells of innate (macro-
phages, dendritic cells (DCs), natural killer (NK), and natural
killer T (NKT) cells) and acquired immunity (T and B lym-
phocytes) [5]. In the majority of patients, activated immune
cells efficiently eliminate the virus and the disease is either
asymptomatic or manifested by fever, cough, and mild lung
inflammation [6]. However, in some patients, SARS-
CoV-2 overactivates immune cells, eliciting strong immune
response in the lungs. Excessive production and release of
inflammatory cytokines and chemokines (interleukin- (IL-)
2, IL-6, IL-7, tumor necrosis factor-alpha (TNF-α), granulo-
cyte colony-stimulating factor (G-CSF), monocyte chemoat-
tractant protein-1 (MCP-1), CXCL10, and CCL3) result in
the severe cytokine storm, followed by the massive influx of
circulating granulocytes and monocytes in the inflamed
lungs, which subsequently leads to the development of lung
edema, dysfunction of the air exchange, and ARDS [4–6].
Currently, no specific drugs or vaccines are available to
cure or prevent COVID-19 infection [7–4]. Several drugs,
known to act on different stages of both the infection and
host response, including Camostat and Nafamostat (which
negatively influence S protein: ACE2/TMPRSS2 interaction),
Remdesivir (that interferes with viral replication), Sarilumab
and Tocilizumab (which inhibit IL-6-driven inflammation),
and Dexamethasone (that prevents SARS-CoV-2-induced
cytokine storm), managed to improve the clinical symptoms
in some SARS-CoV-2-infected patients (Table 1) [7–14].
However, none of these drugs were able to prevent or atten-
uate the cytokine storm in the lungs, and therefore, patients
suffering from SARS-CoV-2-induced ARDS usually need
oxygen supply or mechanical ventilation in addition to anti-
viral therapy [4, 8]. Accordingly, a new therapeutic agent
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Figure 1: Cellular entry of SARS-CoV-2. Envelope, membrane, and spike proteins form the SARS-CoV-2 protein interface to the external
environment. After inhalation, aerosols containing SARS-CoV-2 penetrate the depths of the lungs and cause severe pneumonia, alveolar
injury, and acute respiratory distress syndrome (ARDS). The initial step in the development of SARS-CoV-2-induced ARDS is the
interactions between the SARS-CoV-2 spike protein and angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2
(TMPRSS2) of alveolar type II cells. TMPRSS2 splits the spike protein into two functional subunits, S1 which interacts with ACE2 and S2
that is further cleaved and activated by TMPRSS2. This structural and conformational change in the spike protein facilitates fusion of viral
envelope with the cell membrane of AT2 cells, enabling endocytic entry of the virus in the target cell.
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which will support oxygen supply and, at the same time,
efficiently alleviate the SARS-CoV-2-induced cytokine storm
is urgently needed.
Due to their potent immuno- and angiomodulatory
characteristics, mesenchymal stem cells (MSCs) have been
used in a large number of experimental and clinical trials as
new therapeutic agents for the treatment of inflammatory
and degenerative diseases [15]. MSCs may be easily sourced
from various tissues (bone marrow (BM), blood, umbilical
cord (UC), Wharton’s jelly (WJ), adipose tissue, dental pulp
(DP), synovium, amniotic fluid, etc.) and expanded in vitro
to achieve a sufficient cell number for clinical application
[16]. Due to the reduced expression of major histocompati-
bility class (MHC) II antigens, MSCs are considered as
hypoimmunogenic cells which usually evade allogeneic
rejection after engraftment in MHC-mismatched recipients
[17]. Therefore, MSCs may efficiently suppress detrimental
immune responses and alleviate ongoing lung inflammation
including SARS-CoV-2-induced ARDS [18, 19]. In this
review article, we described molecular mechanisms that are
responsible for MSC-based modulation of immune cells
which play a pathogenic role in the development of SARS-
CoV-2-induced ARDS and we provided a brief outline of
already conducted and ongoing clinical studies that increase
our understanding about the therapeutic potential of MSCs
and their secretome in the therapy of COVID-19-related
ARDS. An extensive literature review was carried out in
May 2020 across several databases (MEDLINE, EMBASE,
Google Scholar, and ClinicalTrials.gov). Keywords used in
the selection were as follows: “mesenchymal stem cells
(MSCs)”, “secretome”, “exosomes (Exos)”, “immunomodu-
lation”, “SARS-CoV-2”, “COVID-19”, and “ARDS”. All jour-
nals were considered, and an initial search retrieved 32
articles. The abstracts of all these articles were subsequently
reviewed by two of the authors (CRH and VV) to check their
relevance to the subject of this manuscript. Eligible studies
had to delineate therapeutic effects of MSCs in SARS-CoV-
2-induced ARDS, and their findings were analyzed in this
review.
2. Molecular and Cellular Mechanisms
Responsible for MSC-Based
Attenuation of ARDS
ARDS is a severe clinical syndrome which develops as a result
of an acute, detrimental systemic inflammatory response in
the lungs [20, 21]. Lung DCs, activated by inhaled pathogens,
increase the expression of costimulatory andMHCmolecules
which migrate to the regional lymph nodes to present
Table 1: The list of the drugs which are tested as therapeutic agents for the treatment of COVID-19.
Therapeutic agent(s) Mechanism of action Expected therapeutic effect Ref. no.
Antiviral drugs
Remdesivir
Inhibition of the viral RNA-dependent
RNA polymerase
Suppressed spreading of SARS-CoV-2 [7–14]Sofosbuvir
Ribavirin
Mefuparib Poly-ADP-ribose polymerase 1 inhibitor Inhibition of SARS-CoV-2 replication [11]
Toremifene Inhibition of the SARS-CoV-2 spike glycoprotein Inhibition of viral entry in AT2 cells [11]
Camostat
Nafamostat
Inhibitor of TMPRSS2 Suppressed spreading of SARS-CoV-2 [9, 10]
IFN-β-1b
Activation of interferon-stimulated genes in AT2
and immune cells
Suppressed replication and spreading of SARS-CoV-2 [7–10]
IVIG Antibody-mediated neutralization of SARS-CoV-2 Inhibition of viral entry in AT2 cells [11]
Immunomodulatory drugs
Dexamethasone Activation of histone deacetylase Reduction of the harmful effects of cytokine storm [7–11]
Sarilumab
Inhibition of IL-6:IL-6R signaling Attenuation of IL-6-driven inflammation [8–10]
Tocilizumab
Anakinra Inhibition of IL-1:IL-1R signaling Attenuation of IL-1-driven inflammation [12]
Baricitinib Janus kinases inhibitor Prevention of dysregulated cytokine production [11]
Melatonine
Upregulation of superoxide dismutase;
downregulation of nitric oxide synthase;
suppression of NF-κB expression
Inhibition of cytokine storm [11]
Combined therapy
Remdesivir+Dexamethasone [10, 11]
IVIG+IFN-β+Dexamethasone [11]
Remdesivir+Baricitinib [10, 11]
IFN-β-1b+Ribavirin [11–14]
Abbreviations: ACE2: angiotensin-converting enzyme 2; TMPRSS2: transmembrane protease serine 2; AT2: alveolar type II cells; IFN-β: interferon beta;
IVIG: intravenous immunoglobulins; IL-6R: interleukin 6 receptor; IL-1: interleukin 1 receptor; NF-κB: nuclear factor kappa-B.
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pathogen-associated molecular patterns (PAMPs) to the
naive T cells [20]. DC-derived IL-12 induces generation of
CXCR3-expressing, TNF-α- and IFN-γ-producing Th1 cells,
while DC-sourced IL-23, IL-1β, IL-6, and TGF-β are respon-
sible for the development of IL-17-producing Th17 cells.
Inflammatory Th1 and Th17 cells activate alveolar macro-
phages and lung-infiltrated neutrophils to produce inflam-
matory mediators (nitric oxide (NO), IL-6, IL-8, TNF-α,
and IL-1β) that cause injury and dysfunction of endothelial
cells increasing vascular permeability [20]. Additionally,
activated lung DCs and alveolar macrophages secrete large
amount of neutrophil-, monocyte-, and lymphocyte-
attracting chemokines (IL-8, CCL2, monocyte chemoattrac-
tant protein-1 (MCP-1), and CXCR3), resulting in the
increased influx of circulating leucocytes in the inflamed
lungs [21]. Activated neutrophils, macrophages, and T cells
release proteolytic enzymes, reactive oxygen species (ROS),
and other potent cytotoxic mediators which induce injury
of AT2 and endothelial cells [21]. Inflammation-induced vas-
cular permeability causes exudation from the plasma to the
alveolar spaces which decreases alveolar fluid clearance and
leads to the development of lung edema. The disruption of
the alveolar-epithelial barrier, accompanied with interstitial
edema and infiltration of inflammatory cells, leads to the
acute respiratory failure [18, 20].
A large number of experimental studies revealed that
MSCs in juxtacrine (cell-to-cell contact-dependent) and/or
paracrine manner (through the production of trophic and
immunoregulatory factors) efficiently suppress ARDS by
modulating phenotype and function of Th1, Th17 cells,
DCs, and alveolar macrophages in the inflamed lungs
(Figure 2) [18, 22]. MSCs prevent proliferation and expan-
sion of inflammatory, IFN-γ- and IL-17-producing CD4+
Th1 and Th17 cells [23]. MSCs express program death
(PD) ligand and induce PD receptor-dependent apoptosis
of effector T cells, alleviating their number in injured lungs
[18]. Additionally, MSCs produce transforming growth
factor-beta (TGF-β) which suppresses activation of the Jak-
Stat signaling pathway in activated T cells, causing the G1 cell
cycle arrest [24]. MSC-sourced HGF acts synergistically with
TGF-β in the MSC-mediated suppression of T cell prolifera-
tion [24]. MSC-derived HGF induces enhanced production
of immunosuppressive IL-10 in monocytes enabling conver-
sion of inflammatory M1 macrophages in alternatively
activated M2 phenotype [24]. M2 macrophages, in turn, pro-
duce anti-inflammatory IL-10 and TGF-β that alleviate
ongoing inflammation and promote repair and regeneration
of injured AT2 cells [18].
MSC-sourced prostaglandin E2 (PGE2) and IL-10 induce
generation of tolerogenic phenotype in DCs alleviating their
antigen-presenting properties [24]. MSC-primed tolerogenic
DCs have reduced capacity for the production of Th1- and
Th17-related cytokines (IL-12, IFN-γ, IL-23, IL-1β, and
IL-6) [18]. Accordingly, reduced presence of activated DCs
and lower numbers of inflammatory Th1 and Th17 cells were
observed in the lungs of MSC-treated animals [18]. MSC-
derived indoleamine 2,3-dioxygenase (IDO) is crucially
important for MSC-based modulation of DC :T cell cross-
talk in inflamed lungs [18]. MSCs in IDO-dependent manner
enhance production of immunosuppressive IL-10 in lung-
infiltrated DCs and suppress expression of costimulatory
and MHC molecules on their membranes, downregulating
their capacity for activation of naive T cells [16, 24]. Addition-
ally, MSC-derived IDO induces expansion of immunosup-
pressive, regulatory FoxP3-expressing T cells and prevents
their transdifferentiation in inflammatory Th17 cells [16].
In addition to the suppression of detrimental immune
response in the inflamed lungs, MSC-based therapy of ARDS
is, at least partially, reliant on their potent angiomodulatory
characteristics [18, 25]. A large number of experimental
and clinical studies demonstrated that injection of MSCs or
their secretome significantly improved oxygen supply in
ischemic tissues enabling their enhanced regeneration and
functional recovery [25]. MSC-dependent neovascularization
is mainly reliant on the capacity to produce large number of
proangiogenic factors (vascular endothelial growth factor
(VEGF), HGF, TGF-β, MCP-1, basic fibroblast growth fac-
tor, platelet-derived growth factor, angiopoietin-1, placental
growth factor, and epidermal growth factor) which support
regeneration of injured and induce generation of new blood
vessels [24, 25].
3. MSC-Based Therapy of ARDS: Evidence from
Experimental Studies and Clinical Trials
Therapeutic potential of MSCs in the treatment of ARDS
has been demonstrated in experimental and clinical studies
[18]. MSCs enhanced regeneration of AT2 and endothelial
cells, alleviated inflammation, reduced pulmonary edema,
improved oxygenation, and prolonged survival of mice
suffering from ARDS [18]. Beneficial effects of MSCs were
due to the enhanced immunosuppression and improved
oxygenation in the injured lungs [18]. MSC-based inhibi-
tion of detrimental immune response in the lungs mainly
relied on the anti-inflammatory effects of MSC-sourced
PGE2 and IL-10 [16, 24]. MSC-derived PGE2 induced
generation of the immunosuppressive M2 phenotype in
alveolar macrophages and increased their capacity for IL-10
production [26]. IL-10, released by MSCs and M2 macro-
phages, attenuated secretion of inflammatory TNF-α in
lung-infiltrated lymphocytes and inhibited production of
ROS and other inflammatory mediators in neutrophils and
monocytes [26]. MSC-derived proresolving mediator lipoxin
A4 was mainly responsible for reduced pulmonary edema
[27], while MSC-sourced VEGF and HGF improved vascu-
larization and oxygenation in injured lungs by promoting
generation of new blood vessels and by preventing apoptosis
of injured endothelial cells [28, 29].
In a similar manner as it was observed in mice, intrave-
nous injection of MSCs was well tolerated in patients who
suffered from moderate and severe ARDS [30, 31]. As
noticed in a clinical trial conducted byWilson and colleagues
(NCT01775774), adverse events, clinical instability, or dose-
limiting toxicity was not observed in any of the nine patients
that received allogeneic BM-MSCs (1, 5, or 10 million
cells/kg) [30]. Based on these promising results, Matthay
and colleagues conducted a larger randomized, multicenter,
phase 2 clinical study in five university medical centers in
4 Analytical Cellular Pathology
the United States (NCT02097641). The trial enrolled 60 adult
ARDS patients who intravenously received either a single
dose of allogeneic BM-MSCs (10million cells/kg; 40 patients)
or placebo (Plasma-Lyte A; 20 patients) [31]. One of the
MSC-treated patients had a fatal cardiopulmonary arrest 20
hours after MSC injection, but the authors explained that this
patient had a preexisting history of coronary artery disease
and concluded that his death was not a consequence of
MSC infusion [31]. Accordingly, as the most important find-
ing of their study, Matthay and colleagues highlighted that
intravenous administration of MSCs was a safe therapeutic
approach for the treatment of patients with moderate and
severe ARDS [31]. Although clinical parameters did not dif-
fer significantly between MSC and placebo-treated patients,
post hoc analyses showed a trend for improvement in the
oxygenation index in MSC-treated patients [31]. However,
it should be noted that Matthay and colleagues indicated that
this analysis was limited because of some missing data and
that MSC-induced improvement in oxygenation index
should not be overinterpreted as a favorable finding until it
will be assessed further in a larger clinical trial [31]. Intrigu-
ingly, mortality at 28 and 60 days was not significantly higher
in the MSC group than in the placebo group. The number of
ventilator-free and organ-failure-free days was not signifi-
cantly lower in the MSC group while the number of
intensive-care-free days was higher in the placebo group,
IL-6
MSC
M1 M𝜑
M2 M𝜑
Th1 cells
Th17 cells
HGF
IL-10
inflammation
repair of injured 
AT2 cells
regeneration of 
injured AT2 cells IL-10
TGF-𝛽
TGF-𝛽
Monocyte
MSC
Th17 cells
HGF
IL-12
IFN-𝛾
IL-23
IL-1𝛽
DC
DC
Tolerogenic
DC
IL-10
IL-10 production
co-stimulatory molecules
expression of MHC
capacity for activation
of naïve T cells
T cells FoxP3+
T regs
IDO
IDO
Stimulation
Inhibition
MSC
Blood vessel
VEGF
HGF
TGF-𝛽
MCP-1
bFGF
PDGF
Ang1
PGF
EGF
oxygen supply in ischemic tissues 
regeneration in ischemic tissues
functional recovery
regeneration of injured blood vessels
generation of new blood vessels 
Lungs
M
SCs 
ARDS
A
B
C
EVs
EVs
MSC
PDL PD
HGF
T cell
T cell
T cell
apoptosis
proliferation
EVs
Alveolus
Figure 2: Molecular mechanisms responsible for MSC-based attenuation of ARDS. MSCs, in juxtacrine (cell-to cell-contact dependent) and
paracrine manner (through the production of immunomodulatory factors), alleviate lung inflammation and ARDS by suppressing
proliferation and effector functions of inflammatory M1 macrophages and Th1 and Th17 cells (a) and by inducing generation of
tolerogenic DCs and expansion of immunosuppressive Tregs (b). Through the production of angiomodulatory factors, MSCs improve
oxygen supply enabling enhanced regeneration and functional recovery from ARDS.
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suggesting that MSC-based therapy was less effective than
placebo [31]. Matthay and colleagues explained that these
differences were most probably a consequence of the fact
that, according to the baseline respiratory variables (minute
ventilation, respiratory rate, and oxygenation index), patients
who were selected for MSC treatment had more severe respi-
ratory failure than patients who were assigned to the placebo
group [31]. Despite this reasonable explanation, the high dis-
ease severity score noticed in MSC-treated patients raises
serious concerns about the therapeutic efficacy of MSCs in
ARDS treatment and should be evaluated in detail in upcom-
ing larger clinical trials.
4. Therapeutic Potential of MSCs in the
Treatment of SARS-CoV-2-Induced ARDS
Beneficial effects of MSCs in the treatment of SARS-CoV-2-
induced pneumonia and ARDS have been demonstrated
in a clinical study conducted by Leng and coworkers
(Figure 3) [32]. They demonstrated that systemic, intrave-
nous administration of MSCs (1 × 106 cells/kg) efficiently
alleviated lung inflammation and significantly improved pul-
monary function in patients suffering from SARS-CoV-2-
induced pneumonia [32]. Ten confirmed COVID-19 patients
were enrolled in this study. MSCs were transplanted in 1
patient with critically severe COVID-19 and 4 patients with
severe and 2 patients with mild disease, while 3 patients with
severe COVID-19, who received placebo, were assigned to
the control group. According to the protocol, MSCs were
injected when COVID-19-related symptoms and/or signs
were getting worse, despite the use of standard medicaments
[32]. Infusion-related reactions, allergies, secondary infec-
tions, and life-threatening adverse events were not observed
in MSC-treated patients during the 14 days of follow-up,
indicating that systemic administration of MSCs was a safe
therapeutic approach for the treatment of COVID-19
patients. Evaluation of COVID-19-related symptoms and
signs (fever (38:5°C ± 0:5°C), shortness of breath, cough, sore
throat, and weakness) and the analysis of clinical, laboratory,
and radiological outcomes (plasma levels of C-reactive pro-
tein (CRP) and cytokines, total number of lymphocytes and
their subpopulations in the blood, the oxygen saturation,
respiratory rate, and chest computed tomography (CT))
revealed that MSCs efficiently attenuate SARS-CoV-2-
induced pneumonia and ARDS [32]. About 2 to 4 days after
MSC transplantation, all COVID-19-related symptoms dis-
appeared in all patients, and the oxygen saturations rose to
≥95% at rest, with or without oxygen uptake (5 liters per
minute). Importantly, the oxygen saturation, without supple-
mentary oxygen, rose from 89% to 98% in MSC-treated
patients with critically severe disease, suggesting that pulmo-
nary alveoli completely regained their air-exchange function.
Both fever and shortness of breath disappeared on the 4th
M
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Figure 3: MSC-based effects observed in a patient with critically severe COVID-19 infection. MSCs significantly improved oxygenation,
suppressed detrimental immune response in the lungs, alleviated systemic inflammation, and attenuated SARS-CoV-2 induced ARDS in a
patient with critically severe COVID-19 infection.
6 Analytical Cellular Pathology
day after MSC transplantation. CT findings confirmed
beneficial effects of MSCs. Ground-glass opacity, initially
observed in the lungs of critically severe COVID-19 patients,
almost completely disappeared as a result of MSC-based
therapy. Two weeks after MSC infusion, only little ground-
glass opacity was locally noticed in the lungs of MSC-
treated patients, confirming MSC-dependent attenuation of
lung inflammation. Additionally, 4 days after MSC adminis-
tration, the levels of aspartic aminotransferase, creatine
kinase, and myoglobin decreased to normal reference values,
indicating that MSCs improved cardiac, liver, and kidney
functions in COVID-19 patients, preventing the develop-
ment of SARS-CoV-2-induced multiple organ dysfunction
syndrome [32].
Importantly, MSCs suppressed detrimental immune
responses in the lungs and alleviated systemic inflammation
in COVID-19 patients [32]. The mass cytometry results of
peripheral blood mononuclear cells revealed that MSCs, 6
days after transplantation, completely altered the phenotype
of immune cells in SARS-CoV-2-infected patients. Signifi-
cant decrease of inflammatory, overactivated CXCR3-
expressing NK cells and CD4+ and CD8+ T lymphocytes
(which cause the cytokine storm in SARS-CoV-2 injured
lungs) and significant increase in immunosuppressive,
regulatory DCs and Tregs (which promote repair and regen-
eration of inflamed lungs) were observed in the blood of
MSC-treated patients with critically severe disease [32]. In
line with these findings, remarkably increased anti-
inflammatory IL-10 and significantly decreased CRP and
TNF-α were observed in plasma samples of MSC-treated
patients, confirming MSC-based suppression of detrimental
immune response in the lungs and alleviation of systemic
inflammation in COVID-19 patients [32].
RNA-seq analysis of transplanted MSCs revealed that
potent immunosuppressive and proangiogenic properties of
MSCs were responsible for their therapeutic effects in
COVID-19 treatment [32]. MSC-based improvement in
oxygen supply could be a consequence of increased expres-
sion of angiomodulatory factors VEGF, EGF, and FGF, while
enhanced expression of anti-inflammatory TGF-β and HGF
could be responsible for MSC-dependent immunosuppres-
sion. Importantly, RNA-seq analysis revealed that MSCs
did not express ACE2 and TMPRSS2 [32]. Therefore, it is
highly expected that MSCs could not be infected by SARS-
CoV-2.
5. MSC-Based Therapy of SARS-CoV-2-Induced
Lung Injury: Ongoing Clinical Trials
Promising results obtained by Leng and colleagues [32]
encouraged many research groups to conduct clinical trials
which are going to further explore and confirm therapeutic
potential of MSCs in the treatment of SARS-CoV-2-induced
pneumonia and ARDS.
Wang and coworkers are currently recruiting 90 COVID-
19 patients for participation in a prospective, double-blind,
multicenter, randomized clinical trial which will evaluate ther-
apeutic effects of MSCs in the treatment of severe SARS-CoV-
2-induced pneumonia (NCT04288102). The experimental
group will consist of 60 patients who will, in addition to con-
ventional treatment, intravenously receive 3 doses of MSCs
(4 × 107 cells per dose, injected on days 0, 3, and 6), while
the control group will consist of 30 patients who are going to
receive combination of conventional treatment and placebo.
Beneficial effects of MSCs in alleviation of lung injury will be
evaluated by chest CT, Modified Medical Research Council
dyspnea scale, 6-minute walk test, maximum vital capacity,
diffusing capacity, oxygen saturation, and oxygenation index,
while MSC-based immunosuppression will be examined by
the immunophenotyping of peripheral blood mononuclear
cell analysis of COVID-19 patients during the 90 days of
follow-up.
Karaoz and colleagues recently elicited a clinical trial in
which patients suffering from SARS-CoV-2-induced lung
injury will either receive standard antiviral therapy or MSCs
(NCT04392778). MSCs (3 × 106/infusion) will be intrave-
nously injected in 10 COVID-19 patients in 3 doses, at days
1, 3, and 6. The estimated study completion date is Septem-
ber 2020.
A large randomized, double-blind, placebo-controlled clin-
ical trial designed by Gelijns and coworkers (NCT04371393)
is currently recruiting patients. According to the study pro-
tocol, 300 patients suffering from SARS-CoV-2-induced
ARDS will be assigned to either the experimental group
(patients will intravenously receive MSCs (remestemcel-L)
plus standard of care) or the control group (will receive
placebo (Plasma-Lyte) plus standard of care). MSCs
(2 × 106 kg) or placebo will be administered twice during
the first week of treatment, specifically with the second
infusion at 4 days following the first infusion. Changes
from baseline in (a) severity of ARDS according to Berlin
Criteria, (b) Clinical Improvement Scale, and (c) serum
levels of inflammatory markers (CRP, IL-6, IL-8, and
TNF-α) will be used for the evaluation of MSC-based
therapeutic effects. Patients will be followed for 90 days, while
pulmonary symptoms will be assessed at 6 and 12 months.
The estimation study completion date is April 2022.
González-Vallinas and colleagues will be conducting a
double-blind, placebo-controlled, randomized clinical trial
in which 24 patients with severe COVID-19 pneumonia will
receive either single dose of MSCs (1 million cells/kg) or pla-
cebo by intravenous injection (NCT04361942). In addition
to the analysis of MSC-based therapeutic effects on lung
function, results of this study should further emphasize the
importance of MSC-dependent immunomodulation for the
beneficial effects of MSCs in alleviation of SARS-CoV-2-
induced lung injury and inflammation. For this purpose,
González-Vallinas and coworkers will analyze whether MSCs
altered total number and phenotype of circulating NK cells
and T and B lymphocytes and will determine serum levels
of inflammatory (IL-6, TNF-alpha) and immunosuppressive
(IL-10) cytokines. The study is currently recruiting patients,
and the estimated completion date is December 2020.
In the clinical trial which is currently recruiting patients
(NCT042521188), Wang and colleagues will analyze whether
MSCs could enhance therapeutic effects of conventional
antiviral drugs in the treatment of SARS-CoV-induced pneu-
monia. From 20 recruited patients, 10 patients will receive
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conventional treatment while the other 10 patients will
receive combination of conventional treatment and MSCs
(3 × 107 cells), which will be intravenously injected 3 times
(at days 0, 3, and 6). Improvement of clinical symptoms
(duration of fever, restoration of respiratory, liver, and kid-
ney function), phenotype of circulating T cells, and 28-day
mortality of MSC-treated COVID-19 patients will be moni-
tored for 180 days. The estimated study completion date is
December 2021.
A similarly designed study, which will evaluate the bene-
ficial effects of DP-MSCs in the treatment of severe pneumo-
nia of COVID-19 patients, is currently recruiting patients
(NCT04336254). Twenty patients suffering from severe
SARS-CoV-2-induced pneumonia (manifested by respira-
tory distress, respiratory rate > 30 times/min; resting oxygen
saturation of 93% or less; arterial partial pressure of
oxygen/oxygen concentration 300mmHg) will be randomly
divided in two groups to receive either conventional treat-
ment or combination of conventional therapy and DP-
MSCs (3 × 107 cells) which will be intravenously injected
on days 1, 4, and 7. DP-MSC-mediated alleviation of lung
inflammation will be confirmed by CT while total number
of CD16+/CD56+ NK cells, CD3+/CD4+/CD8+ T lympho-
cytes, and CD19+ B cells in the blood; titer of IgA, IgG,
IgM, and IgE; and concentration of Th1-related (IL-1β,
IL-2, TNF-α, and IFN-γ) and Th2-related cytokines (IL-4,
IL-6, and IL-10) will be determined to evaluate MSC-
dependent suppression of detrimental immune response.
The estimated study completion date is March 2021.
Therapeutic potential of WJ-MSCs in the treatment of
COVID-19-related lung injury and inflammation will be
explored in clinical trials elicited by Al Zoubi et al.
(NCT04313322), Torres et al. (NCT04390139), and Monsel
et al. (NCT04333368). Al Zoubi and colleagues will recruit
5 COVID-19 patients who will intravenously receive 3 doses
ofWJ-MSCs (1 × 106 cells/kg). Each dose ofWJ-MSCs will be
given 3 days apart from the previous dose. Improvement of
clinical symptoms in WJ-MSC-treated patients, including
duration of fever, respiratory distress, pneumonia, cough,
and sneezing, will be monitored for three weeks. This study
is currently recruiting patients, and the estimated completion
date is September 2020. Torres and colleagues will treat 30
SARS-CoV-2-infected patients with a combination of
standard antiviral therapy and WJ-MSCs (1 × 106 cells/kg),
which will be intravenously injected at days 1 and 3. WJ-
MSC-treated patients will be followed up on days 3, 5, 7,
14, 21, and 28. After the completion of the study, lung func-
tion of WJ-MSC-treated patients will be analyzed at 3
months, 6 months, and 12 months as long-term follow-up.
Monsel and colleagues are currently recruiting 40 patients
suffering from SARS-CoV-2-induced ARDS who are going
to receive either WJ-MSCs (1 × 106 cells/kg) or placebo
(NaCl 0.9%) via a peripheral or central venous line at days
1, 3, and 5. Lung injury score, oxygenation index, and serum
levels of immuno- and angiomodulatory cytokines (IL-1,
IL-6, IL-8, TNF-α, IL-10, and TGF-β) will be determined
to evaluate therapeutic effects of WJ-MSCs in attenuation
of SARS-CoV-2-induced ARDS. The estimated study com-
pletion date is July 2021.
Ricordi and coworkers are currently recruiting patients
with SARS-CoV-2-induced ARDS for participation in the
clinical trial that will investigate safety and efficacy of UC-
MSCs (NCT04355728). According to the study protocol, 24
patients will be randomly assigned to either the experimental
or control group, respectively. Participants from the experi-
mental group will be treated with two intravenous infusions
of UC-MCSs (1 × 108 cells/injection) in addition to standard
of care treatment. The first infusion will be administered
within 24 hours of study enrollment, and the second infusion
will be administered within the next 48 hours. Patients from
the control group will only receive standard of care treat-
ment. Safety will be defined by the incidence of severe adverse
events while efficacy will be determined by CT, biochemi-
cal, and laboratory parameters of lung, liver, and kidney
function.
Aranzasti et al. (NCT04366271), McAuley et al.
(NCT03042143), and Wang et al. (NCT04269525) are also
going to evaluate the therapeutic effects of UC-MSCs in the
treatment of COVID-19-related ARDS. The study led by
Aranzasti and colleagues is currently recruiting 106 patients
who will be randomly divided into the UC-MSC-treated
and standard of care-treated groups. UC-MSC-treated
patients will receive a single infusion of UC-MSCs. The exact
number of injected UC-MSCs is not defined for this study.
McAuley and coworkers will recruit 75 patients who will
either receive UC-MSCs or placebo (Plasma-Lyte). Alter-
ation in oxygenation index and incidence of serious adverse
events will be monitored in UC-MSC-treated patients up to
28 days after UC-MSC infusion. The estimated study
completion date is October 2022. In a clinical study led by
Wang and colleagues (NCT04269525), SARS-CoV-2-
infected patients will receive UC-MSCs (3:3 × 107 cells/
50ml/bag, 3 bags each time). UC-MSCs will be infused intra-
venously at days 1, 3, 5, and 7. In addition to the assessment
of pulmonary function, MSC-based immunosuppression will
be determined by immunophenotyping of peripheral blood
mononuclear cells and by the measurement of serum levels
of TNF-α, IFN-γ, IL-2, IL-4, IL-6, IL-18, and IL-10. The esti-
mated study completion date is September 2020.
6. Therapeutic Potential of MSC-Derived
Extracellular Vesicles in Attenuation of
SARS-CoV-2-Induced ARDS
Several lines of evidence demonstrated that most of the MSC-
based beneficial effects in alleviation of lung injury were
relied on immunomodulatory capacity of MSC-derived
extracellular vesicles (EVs): apoptotic bodies, microvesicles,
and exosomes (MSC-Exos) [18, 33]. Intravenously injected
MSC-EVs accumulate in the lungs and, due to their
nanosized dimension and lipid-enriched membrane, easily
penetrate in the lung-infiltrate immune cells to modulate
their phenotype and function [33]. MSC-EVs contain
MSC-derived bioactive molecules (microRNAs (miRNAs),
enzymes, cytokines, chemokines, and immunomodulatory
and growth factors) that generate a tolerogenic phenotype
in lung-infiltrated DCs and macrophages which results in
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enhanced expansion of immunosuppressive Tregs in injured
lungs and leads to the alleviation of ongoing inflammation
[18, 33]. As recently demonstrated by us and others
[34, 35], in a similar manner as their parental cells, MSC-
EVs efficiently attenuated detrimental immune responses in
the lungs and promoted enhanced lung repair and regenera-
tion. Reduced expression of costimulatory molecules, down-
regulated production of Th1- (IL-12, TNF-α, and IFN-γ) and
Th17-inducing cytokines (IL-1, IL-6, and IL-23), and attenu-
ated capacity of antigen-presentation capacity were noticed
in DCs and macrophages isolated from the inflamed lungs
of MSC-EV-treated animals [34, 35]. Consequently, signifi-
cantly lower number of lung-infiltrating, inflammatory,
TNF-α- and IFN-γ-producing Th1 cells and IL-17-
producing Th17 cells and significantly higher number of
immunosuppressive, IL-10- and TGF-β-secreting Tregs were
found in MSC-EV-treated mice [34, 35].
In line with these preclinical data are results obtained in a
clinical study conducted by Sengupta and colleagues [36].
Single intravenous injections of BM-MSC-derived Exos
(15ml, ExoFlo) were given to the 24 COVID-19 patients
who met the criteria for moderate-to-severe ARDS. BM-
MSC-Exos were well tolerated; no infusion reaction or
adverse events were observed within the first 72 hours
after BM-MSC-Exo administration [36]. Importantly, sin-
gle intravenous infusion of BM-MSC-Exos significantly
improved lung function, alleviated systemic inflammation,
and increased total number of circulating neutrophils and
lymphocytes in majority of COVID-19 patients [36]. BM-
MSC-Exos efficiently attenuated SARS-CoV-2-related ARDS
in 71% of BM-MSC-Exo-treated patients (17/24) who
completely recovered within a week after intravenous
administration of ExoFlo. Assessment of pulmonary function
parameters revealed significantly improved oxygenation in
BM-MSC-Exo-treated patients. An average pressure of arte-
rial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2)
significantly increased in 20/24 of BM-MSC-Exo-treated
patients, 3 days after ExoFlo infusion. The mean increase of
PaO2/FiO2 from baseline was 191% at day 14 and was a
strong predictor of hospital discharge for BM-MSC-treated
patients. Biochemical analysis confirmed beneficial effects
of BM-MSC-Exos. The mean reduction of CRP was 77%,
the mean reduction of ferritin was 43%, and the mean reduc-
tion of D-dimer was 42% between baseline and values mea-
sured on day 5 [36]. Additionally, 5 days after systemic
administration, BM-MSC-Exos significantly improved abso-
lute number of circulating neutrophils and CD4+ and CD8+
T cells, as well as prevented development of severe immuno-
deficiency in SARS-CoV-2-infected patients. Despite these
promising results, it should be noted that BM-MSC-Exo-
based therapy was not effective in 29% (7/24) of COVID-19
patients. Four patients passed away for reasons unrelated to
the BM-MSC-Exo administration, while 3 patients remained
critically ill and required mechanical ventilation and inten-
sive care [36].
In addition to the study published by Sengupta and
colleagues, an additional clinical trial is going to investigate
therapeutic potential of MSC-EVs in the treatment of
COVID-19-related ARDS. Shahverdi and colleagues are cur-
rently recruiting 60 critically ill SARS-CoV-infected patients
suffering from ARDS to participate in a randomized clinical
trial which will evaluate efficacy of MSCs and MSC-EVs in
the treatment of COVID-19-related ARDS (NCT04366063).
Patients will be randomly assigned to 3 groups to receive
the following: two doses of MSCs (1 × 108 cells; intravenously
at days 0 and 2; experimental group 1), two doses of MSCs
(1 × 108 cells) plus two doses of MSC-EVs (MSCs will be
given at days 0 and 2 while MSC-EVs will be injected on
day 4 and day 6; experimental group 2), and placebo (control
group). Importantly, all patients from the experimental and
control groups will receive conventional antiviral therapy
and supportive care for ARDS treatment. Improvement of
clinical symptoms, including duration of fever, respiratory
distress, pneumonia, cough, sneezing, blood oxygen satura-
tion, and 28-day mortality, will be analyzed to confirm
efficacy of MSCs and their EVs in alleviation of SARS-CoV-
2-induced ARDS during the 28-day follow-up.
7. Conclusions
Results obtained in two previously conducted clinical trials
demonstrated that MSCs and their EVs efficiently suppressed
detrimental immune responses in the lungs, alleviated ongo-
ing inflammation, and significantly improved respiratory
function in patients suffering from SARS-CoV-2-induced
ARDS [32, 36]. Importantly, aggravation of COVID-19-
related symptoms and adverse effects related to the infusion
of MSC/MSC-Exos were not reported [32, 36], suggesting
that administration of MSCs and their EVs was a safe and
effective therapeutic approach for the treatment of SARS-
CoV-2 infected patients.
Despite these promising results, it should be noted that
the safety and efficacy of MSCs/MSC-EVs were, in both stud-
ies, evaluated in a small number of COVID-19 patients. Leng
and colleagues evaluated therapeutic potential of MSCs in 7
COVID-19 patients, and almost all conclusions were made
based on the analysis of MSC-based effects in one, critically
ill patient [32]. Sengupta and coworkers examined the thera-
peutic potential of MSC-Exos in 24 patients and showed that
MSC-Exos were not able to improve the respiratory function
in 7 patients [36].
Additionally, it should be emphasized that MSCs are not
constitutively immunosuppressive [37]. MSCs may alter
their phenotype and become inflammatory cells if they
engraft in the microenvironment with low levels of inflamma-
tory cytokines, particularly IFN-γ and TNF-α [17, 37, 38].
These findings should be carefully considered in upcoming
COVID-19-related clinical trials to avoid potential undesirable
interactions between MSCs and antiviral drugs with immuno-
modulatory properties.
Since SARS-CoV-2 causes morbidity and mortality
which escalate throughout the world, there might be tempta-
tion to progress with the clinical use of novel and unproven
therapeutics. A large number of clinical trials are currently
recruiting COVID-19 patients for MSC-related studies, and
it is highly expected that these studies will provide important
evidence about the therapeutic potential of MSCs in the
treatment of SARS-CoV-2-induced ARDS. Therefore, with
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consideration to evidence-based science, MSCs and their
secretome should be offered worldwide as a new remedy for
the treatment of COVID-19 infection only if results from
upcoming clinical trials confirm their safety and efficacy.
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